INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in West Pharmaceutical Services, Inc. of Class Action Lawsuit and Upcoming Deadlines - WST

Core Viewpoint - A class action lawsuit has been filed against West Pharmaceutical Services, Inc. for potential securities fraud and unlawful business practices [2][3]. Group 1: Lawsuit Details - The lawsuit involves allegations against West and certain officers and/or directors regarding securities fraud or other unlawful business practices [2]. - Investors who purchased West securities during the Class Period can request to be appointed as Lead Plaintiff by July 7, 2025 [3]. Group 2: Financial Performance - On February 13, 2025, West issued weak revenue and earnings forecasts for 2025, attributing the disappointing guidance to challenges in its Contract Manufacturing segment [3]. - The company lost two major continuous glucose monitoring customers who transitioned to in-house manufacturing, which West did not participate in due to unmet financial thresholds [3]. - West's SmartDose wearable injector devices are expected to be "margin dilutive" in 2025, prompting the company to consider various options to improve its economics [3]. - Following the announcement, West's stock price dropped by $123.17 per share, or 38.2%, closing at $199.11 per share on February 13, 2025 [3].